NCT01258530View on ClinicalTrials.gov

A Study to Evaluate the Bioequivalence of Over-encapsulated Oseltamivir Capsules to Marketed Oseltamivir Capsules in Healthy Volunteers

PHASE1CompletedINTERVENTIONAL

Enrollment

28

Participants

Timeline

Start Date

December 20, 2010

Primary Completion Date

February 3, 2011

Study Completion Date

February 3, 2011

Conditions

Influenza, Human

Interventions

DRUG

over-encapsulated oseltamivir

75 mg once

DRUG

oseltamivir

75 mg once

Trial Locations (1)

14202

GSK Investigational Site, Buffalo

Sponsors

Lead Sponsor

GlaxoSmithKline

All Listed Sponsors

lead

GlaxoSmithKline

INDUSTRY

NCT01258530 - A Study to Evaluate the Bioequivalence of Over-encapsulated Oseltamivir Capsules to Marketed Oseltamivir Capsules in Healthy Volunteers | Biotech Hunter | Biotech Hunter